These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1178 related articles for article (PubMed ID: 25945865)

  • 1. Effect of Carvedilol on Serum Heart-type Fatty Acid-binding Protein, Brain Natriuretic Peptide, and Cardiac Function in Patients With Chronic Heart Failure.
    Sun YP; Wei CP; Ma SC; Zhang YF; Qiao LY; Li DH; Shan RB
    J Cardiovasc Pharmacol; 2015 May; 65(5):480-4. PubMed ID: 25945865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Preliminary study on the effect of carvedilol on children with primary endocardial fibroelastosis].
    Li R; Yi QJ; Qian YR; Liu XY; Zhong JR; Bai YH; Mi Q; Li XL
    Zhonghua Er Ke Za Zhi; 2008 Sep; 46(9):684-7. PubMed ID: 19099859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction.
    Takeda Y; Fukutomi T; Suzuki S; Yamamoto K; Ogata M; Kondo H; Sugiura M; Shigeyama J; Itoh M
    Am J Cardiol; 2004 Aug; 94(4):448-53. PubMed ID: 15325927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myocardial contractile reserve under low doses of dobutamine and improvement of left ventricular ejection fraction with treatment by carvedilol.
    Jourdain P; Funck F; Fulla Y; Hagege A; Bellorini M; Guillard N; Loiret J; Thebault B; Desnos M
    Eur J Heart Fail; 2002 Jun; 4(3):269-76. PubMed ID: 12034151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased low-grade inflammation is associated with lack of functional response to carvedilol in patients with systolic heart failure.
    Fragasso G; Spoladore R; Maranta F; Corti A; Lattuada G; Colombo B; Locatelli M; Salerno A; Calori G; Briceno L; Alfieri AB; Perseghin G; Margonato A
    J Cardiovasc Med (Hagerstown); 2013 Jan; 14(1):49-56. PubMed ID: 23018486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum biomarkers and clinical outcomes in heart failure patients treated de novo with carvedilol.
    Nessler J; Nessler B; Golebiowska-Wiatrak R; Palka I; Gackowski A; Kitlinski M; Melander O; Fedorowski A
    Cardiol J; 2013; 20(2):144-51. PubMed ID: 23558872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carvedilol reduces elevated B-type natriuretic peptide in dialyzed patients without heart failure: cardioprotective effect of the beta-blocker.
    Kojima M; Sato K; Kimura G; Ueda R; Dohi Y
    J Cardiovasc Pharmacol; 2007 Apr; 49(4):191-6. PubMed ID: 17438403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Changes of heart-type fatty acid-binding protein in children with chronic heart failure and its significance].
    Sun YP; Wang WD; Ma SC; Wang LY; Qiao LY; Zhang LP
    Zhongguo Dang Dai Er Ke Za Zhi; 2013 Feb; 15(2):99-101. PubMed ID: 23428121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of carvedilol on B-type natriuretic peptide and cardiac function in patients with heart failure and persistent atrial fibrillation.
    Khand AU; Chew PG; Douglas H; Jones J; Jan A; Cleland JG
    Cardiology; 2015; 130(3):153-8. PubMed ID: 25660493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of beta-blockers on left ventricular dyssynchrony and reverse remodeling in idiopathic dilated cardiomyopathy: A randomized trial of carvedilol and metoprolol.
    Kaya MG; Sarli B; Akpek M; Kaya EG; Yarlioglues M; Topsakal R; Lam YY
    Cardiol J; 2014; 21(4):434-41. PubMed ID: 24142686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beta-blockade therapy in chronic heart failure: diastolic function and mitral regurgitation improvement by carvedilol.
    Capomolla S; Febo O; Gnemmi M; Riccardi G; Opasich C; Caporotondi A; Mortara A; Pinna GD; Cobelli F
    Am Heart J; 2000 Apr; 139(4):596-608. PubMed ID: 10740140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of carvedilol on plasma adiponectin concentration in patients with chronic heart failure.
    Yamaji M; Tsutamoto T; Tanaka T; Kawahara C; Nishiyama K; Yamamoto T; Fujii M; Horie M
    Circ J; 2009 Jun; 73(6):1067-73. PubMed ID: 19367012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decrease in plasma brain natriuretic peptide level in the early phase after the start of carvedilol therapy is a novel predictor of long-term outcome in patients with chronic heart failure.
    Fujimura M; Akaike M; Iwase T; Yoshida S; Sumitomo Y; Yagi S; Ikeda Y; Hashizume S; Aihara K; Nishiuchi T; Yasumura Y; Matsumoto T
    Acta Cardiol; 2009 Oct; 64(5):589-95. PubMed ID: 20058503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma brain natriuretic peptide as a novel therapeutic indicator in idiopathic dilated cardiomyopathy during beta-blocker therapy: a potential of hormone-guided treatment.
    Kawai K; Hata K; Takaoka H; Kawai H; Yokoyama M
    Am Heart J; 2001 Jun; 141(6):925-32. PubMed ID: 11376305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concentration of BNP, endothelin 1, pro-inflammatory cytokines (TNF-alpha, IL-6) and exercise capacity in patients with heart failure treated with carvedilol.
    Nessler J; Nessler B; Kitliński M; Gackowski A; Piwowarska W; Stepniewski M
    Kardiol Pol; 2008 Feb; 66(2):144-51; discussion 152-3. PubMed ID: 18344152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure.
    Sliwa K; Norton GR; Kone N; Candy G; Kachope J; Woodiwiss AJ; Libhaber C; Sareli P; Essop R
    J Am Coll Cardiol; 2004 Nov; 44(9):1825-30. PubMed ID: 15519014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.
    Jabbour A; Macdonald PS; Keogh AM; Kotlyar E; Mellemkjaer S; Coleman CF; Elsik M; Krum H; Hayward CS
    J Am Coll Cardiol; 2010 Apr; 55(17):1780-7. PubMed ID: 20413026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BNP levels predict outcome in pediatric heart failure patients: post hoc analysis of the Pediatric Carvedilol Trial.
    Auerbach SR; Richmond ME; Lamour JM; Blume ED; Addonizio LJ; Shaddy RE; Mahony L; Pahl E; Hsu DT
    Circ Heart Fail; 2010 Sep; 3(5):606-11. PubMed ID: 20573993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brain natriuretic peptide response is heterogeneous during beta-blocker therapy for congestive heart failure.
    Yoshizawa A; Yoshikawa T; Nakamura I; Satoh T; Moritani K; Suzuki M; Baba A; Iwanaga S; Mitamura H; Ogawa S
    J Card Fail; 2004 Aug; 10(4):310-5. PubMed ID: 15309697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Diagnostic value of plasma concentration of pro-brain natriuretic peptide in congestive heart failure in pediatric patients with ventricular septal defects].
    Wu YR; Chen SB; Huang MR; Zhang YQ; Sun K; Chen S
    Zhonghua Er Ke Za Zhi; 2005 Mar; 43(3):161-4. PubMed ID: 15833183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 59.